- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Elicera Therapeutics AB (ELIC)
Elicera Therapeutics AB stock price live, this page displays ST ELIC stock exchange data. View the ELIC premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Elicera Therapeutics AB real time stock price chart below.
What Is the Elicera Therapeutics AB Stock Price Today?
The Elicera Therapeutics AB stock price today is 6.00.
What Is the Stock Symbol for Elicera Therapeutics AB?
The stock symbol for Elicera Therapeutics AB is ""ELIC.""
What Stock Exchange Does Elicera Therapeutics AB Trade On?
Elicera Therapeutics AB is listed and trades on the Stockholm stock exchange.
Is Elicera Therapeutics AB a Good Stock to Buy?
Determining whether Elicera Therapeutics AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ELIC quote. (ISIN: SE0015382080)
What Is the Elicera Therapeutics AB Stock Price Today?
The Elicera Therapeutics AB stock price today is 6.00.
What Is the Stock Symbol for Elicera Therapeutics AB?
The stock symbol for Elicera Therapeutics AB is ""ELIC.""
What Stock Exchange Does Elicera Therapeutics AB Trade On?
Elicera Therapeutics AB is listed and trades on the Stockholm stock exchange.
Is Elicera Therapeutics AB a Good Stock to Buy?
Determining whether Elicera Therapeutics AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ELIC quote. (ISIN: SE0015382080)
Stockholm
Currency in SEK
6.00
-0.12(-1.96%)
Closed·
Fair Value
An estimate of a Elicera Therapeutics AB's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.00
6.33
52 wk Range
1.26
7.48
ELIC Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 15 days
1/2
Fair Value
An estimate of a Elicera Therapeutics AB's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.006.33
52 wk Range
1.267.48
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ELIC Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Elicera Therapeutics AB's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Elicera Therapeutics AB Company Profile
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden.
Compare ELIC to Peers and Sector
Metrics to compare | ELIC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipELICPeersSector | |
|---|---|---|---|---|
P/E Ratio | −16.1x | −4.5x | −0.5x | |
PEG Ratio | −0.34 | −0.18 | 0.00 | |
Price/Book | 9.2x | 1.3x | 2.6x | |
Price / LTM Sales | 69.9x | 20.7x | 3.3x | |
Upside (Analyst Target) | 6.7% | 0.0% | 42.9% | |
Fair Value Upside | Unlock | 59.5% | 6.2% | Unlock |
Earnings
Latest Release
May 30, 2025
EPS / Forecast
-0.22 / --
Revenue / Forecast
218.86K / --
FAQ
What Stock Exchange Does Elicera Therapeutics AB Trade On?
Elicera Therapeutics AB is listed and trades on the Stockholm Stock Exchange stock exchange.
What Is the Stock Symbol for Elicera Therapeutics AB?
The stock symbol for Elicera Therapeutics AB is "ELIC."
What Is the Elicera Therapeutics AB Market Cap?
As of today, Elicera Therapeutics AB market cap is 291.21M.
What Is Elicera Therapeutics AB's Earnings Per Share (TTM)?
The Elicera Therapeutics AB EPS (TTM) is -0.53.
When Is the Next Elicera Therapeutics AB Earnings Date?
Elicera Therapeutics AB will release its next earnings report on 26 Aug 2025.
From a Technical Analysis Perspective, Is ELIC a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Elicera Therapeutics AB Stock Split?
Elicera Therapeutics AB has split 0 times.
How Many Employees Does Elicera Therapeutics AB Have?
Elicera Therapeutics AB has 2 employees.
What is the current trading status of Elicera Therapeutics AB (ELIC)?
As of 12 Aug 2025, Elicera Therapeutics AB (ELIC) is trading at a price of 6.00, with a previous close of 6.12. The stock has fluctuated within a day range of 6.00 to 6.33, while its 52-week range spans from 1.26 to 7.48.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.